CYTK — Cytokinetics, Incorporated Share News
0.000.00%
Last trade - 00:00- $8.89bn
- $8.87bn
- $88.04m
Cytokinetics heart disease drug meets main goals in late-stage study
Brief: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- Biogen, Eli Lilly, Johnson & Johnson
Brief: Cytokinetics Announces Four Presentations At The American College Of Cardiology Annual Scientific Session & Expo
Cytokinetics Q4 net loss widens
Brief: Cytokinetics Q4 Basic EPS USD -1.5
Brief: Cytokinetics Announces European Commission Approval Of MYQORZO
Brief: Cytokinetics Announces Recipients Of Its Eighth Annual Communications Grant Program
Brief: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule
U.S. RESEARCH ROUNDUP-Alphabet, Micron Technology, Microsoft
U.S. STOCKS ON THE MOVE-UniFirst, Stanley Black & Decker, Janus Henderson
Cytokinetics jumps after FDA approves its drug for rare heart disease
U.S. STOCKS ON THE MOVE-UniFirst, Stanley Black & Decker, Janus Henderson
U.S. STOCKS ON THE MOVE-Nvidia, Velo3D, Fastenal
Cytokinetics rises after FDA approves co's drug for rare heart disease
U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart
NASDAQ RESUMED AT 04:20 PM
Brief: Cytokinetics Announces FDA Approval Of Myqorzo™ (Aficamten)
US FDA approves Cytokinetics' heart disease drug (updated)